21:07 , Jul 26, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 27 profitable biotechs and pharmas are slated to report earnings this week. (A) During market hours in Europe, premarket on U.S. exchanges; (B) Fiscal 1Q Company Date Pre/post mkt 2Q19...
21:23 , Jul 3, 2019 |  BC Extra  |  Clinical News

July 3 Clinical Quick Takes: GSK starts Phase III otilimab RA program; plus Unum, Xofluza and more

Otilimab triggers milestone for MorphoSys MorphoSys AG (Xetra:MOR; NASDAQ:MOR) will receive a milestone payment of €22 million ($27.7 million) after partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) started the Phase III ContRAst program of otilimab to treat...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
00:01 , Jun 26, 2019 |  BC Extra  |  Clinical News

June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more

Minerva rises with insomnia data  Seltorexant (MIN-202) from Minerva Neurosciences Inc. (NASDAQ:NERV) met the primary endpoint of reducing Latency to Persistent Sleep (LPS) at night 1 vs. placebo (p≤0.001) in a Phase IIb trial to...
19:48 , May 3, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 22 profitable biotechs and pharmas are slated to report earnings this week. (A) During trading hours in Europe; premarket on U.S. exchange; (B) Fiscal 4Q; Company Date Pre/post mkt 1Q19...
00:04 , Apr 12, 2019 |  BC Week In Review  |  Clinical News

Poxel's imeglimin meets in first Japanese Phase III for Type II diabetes

Poxel and Sumitomo said imeglimin met the primary endpoint in the Japanese Phase III TIMES 1 trial to treat Type II diabetes. The partners reiterated their plan to submit in 2020 an NDA to Japan’s...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
14:30 , Mar 19, 2019 |  BC Innovations  |  Distillery Therapeutics

ALK2 inhibition for diffuse intrinsic pontine glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting ALK2 could help treat diffuse intrinsic pontine glioma (DIPG) in patients harboring activating ALK2 mutations. In tumorspheres derived from an ALK2-mutant mouse...
23:47 , Mar 4, 2019 |  BC Extra  |  Company News

Management tracks: Astellas, Sanofi China, Zafgen

Astellas promoted James Kellerman to SVP and head of IP legal and Peter Sandor to SVP and primary focus lead for immuno-oncology. Kellerman was VP of IP, Americas region and Sandor was VP, head of...